Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS)

Aurora UK Alpha Updates Share Capital After Treasury Buyback

AIM ImmunoTech Launches $2.7 Million Registered Direct Offering, Private Placement

AIM ImmunoTech announces $2.65M registered direct offering

AIM ImmunoTech prices USD 2.65 million registered direct offering at USD 0.52 a share

AIM ImmunoTech Announces $2.65 Million Financing Priced at-Market Under Nyse American Rules

AIM ImmunoTech Inc trading halted, news pending

Silver Bullet to Quit AIM and Go Private Amid Valuation and Cost Concerns

AIM ImmunoTech registers to sell 31.29M shares of common stock for holders

AIM ImmunoTech: to Offer and Resell up to 31.3 Mln Shares of Common Stock by Selling Stockholders - SEC Filing

Teva put volume heavy and directionally bearish

Aurora UK Alpha Boosts Treasury Stock with Share Buyback

Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

Teva presents positive long-term study data for Austedo

AIM ImmunoTech Says Pancreatic Cancer Drug Has Shown 'Positive Progress' in Phase 2 Study; Shares Rise Pre-Bell

AIM ImmunoTech cites positive mid-year interim progress in Phase 2 Ampligen-Imfinzi pancreatic cancer trial

AIM ImmunoTech - on Track for December 2026 Primary Endpoint Evaluation in Phase 2 Trial

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress From Phase 2 Study Evaluating Ampligen® (Rintatolimod) in Combination With AstraZeneca’s Imfinzi® (Durvalumab) for the Treatment of Pancreatic Cancer

Teva’s Data on Austedo® (Deutetrabenazine) Tablets and Austedo Xr® (Deutetrabenazine) Extended-Release Tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

Options Volatility and Implied Earnings Moves This Week, June 08 – June 11, 2026